Mirum Pharmaceuticals, Inc.
MIRMDrugs in Pipeline
10
Phase 3 Programs
5
Upcoming Catalysts
3
Next Catalyst
Aug 5, 2026
7wMarket Overview
Stock performance and key metrics
4 upcoming, 0 past
Volixibat Phase 2 Results Expected
Primary completion for Volixibat trial (NCT04663308) in Primary Sclerosing Cholangitis
Primary goal achieved in VISTAS Phase IIb trial
Source3 more catalysts beyond 14 days
Start a 7-day free trial to see all upcoming catalysts
Maralixibat
Biliary Atresia
Cholic acid
Inborn Errors of Bile Acid Synthesis
Cholic Acids
Infantile Refsum's Disease
Blinded CDCA 250 mg TID
CTX
Brelovitug (BJT-778)
Chronic Hepatitis D
Ursodeoxycholic Acid
PBC
LUM001 (Maralixibat)
Alagille Syndrome
Volixibat
Primary Biliary Cholangitis
Low dose of MRM-3379
Fragile X Syndrome
LUM001
Alagille Syndrome
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Maralixibat | Phase 3 | Biliary Atresia | - | - |
Cholic acid | Phase 3 | Inborn Errors of Bile Acid Synthesis | - | - |
Cholic Acids | Phase 3 | Infantile Refsum's Disease | - | - |
Blinded CDCA 250 mg TID | Phase 3 | CTX | - | - |
Brelovitug (BJT-778) | Phase 3 | Chronic Hepatitis D | - | - |
Ursodeoxycholic Acid | Phase 2 | PBC | - | - |
LUM001 (Maralixibat) | Phase 2 | Alagille Syndrome | - | - |
Volixibat | Phase 2 | Primary Biliary Cholangitis | - | - |
Low dose of MRM-3379 | Phase 2 | Fragile X Syndrome | - | - |
LUM001 | Phase 2 | Alagille Syndrome | - | - |
Alagille Syndrome
3 drugs in this indication
Inborn Errors of Bile Acid Synthesis
1 drug in this indication
PBC
1 drug in this indication
Fragile X Syndrome
1 drug in this indication
Biliary Atresia
1 drug in this indication
Primary Biliary Cholangitis
1 drug in this indication
CTX
1 drug in this indication
Infantile Refsum's Disease
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)